Sixth Amendment to Loan and Security Agreement, dated March 7, 2024, by and among SLR Investment Corp. (formerly known as Solar Capital Ltd.), as collateral agent, the lenders listed on the signature pages thereto, and Neuronetics, Inc
Exhibit 10.9
CERTAIN INFORMATION IDENTIFIED WITH THE MARK “[***]” HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
SIXTH AMENDMENT TO THE LOAN AND SECURITY AGREEMENT
THIS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this “Agreement”) dated as of March 2, 2020 (the “Effective Date”) among Solar Capital Ltd., a Maryland corporation with an office located at 500 Park Avenue, 3rd Floor, New York, NY 10022 (“Solar”), as collateral agent (in such capacity, together with its successors and assigns in such capacity, “Collateral Agent”), and the lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Solar in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and Neuronetics, Inc., a Delaware corporation with offices located at 3222 Phoenixville Pike, Malvern, Pennsylvania (individually and collectively, jointly and severally, “Borrower”), provides the terms on which the Lenders shall lend to Borrower and Borrower shall repay the Lenders. The parties agree as follows:
1. | DEFINITIONS AND OTHER TERMS |
“Agreement” | Preamble |
“Approved Lender” | Section 12.1 |
“Borrower” | Preamble |
“Claims” | Section 12.2 |
“Collateral Agent” | Preamble |
US-DOCS ###-###-####.3
“Collateral Agent Report” | Exhibit B, Section 5 |
“Communications” | Section 10 |
“Connection Income Taxes” | Exhibit C, Section 1 |
“Default Rate” | Section 2.3(b) |
“Effective Date” | Preamble |
“Event of Default” | Section 8 |
“Excluded Taxes” | Exhibit C, Section 1 |
“FATCA” | Exhibit C, Section 1 |
“Indemnified Person” | Section 12.2 |
“Indemnified Taxes” | Exhibit C, Section 1 |
“Lender” and “Lenders” | Preamble |
“Lender Transfer” | Section 12.1 |
“New Subsidiary” | Section 6.10 |
“Non-Funding Lender” | Exhibit B, Section 10(c)(ii) |
“Open Source Licenses” | Section 5.2(f) |
“Other Connection Taxes” | Exhibit C, Section 1 |
“Other Lender” | Exhibit B, Section 10(c)(ii) |
“Other Taxes” | Exhibit C, Section 1 |
“Perfection Certificate” and “Perfection Certificates” | Section 5.1 |
“Participant Register” | Section 12.1 |
“Recipient” | Exhibit C, Section 1 |
“Register” | Section 12.1 |
“Solar” | Preamble |
“Term A Loan” | Section 2.2(a)(i) |
“Term B Loan” | Section 2.2(a)(ii) |
“Term C Loan” | Section 2.2(a)(iii) |
“Term C Loan Funding Date” | Section 3.4(a) |
“Termination Date” | Exhibit B, Section 8 |
“Term Loan” | Section 2.2(a)(iii) |
“Transfer” | Section 7.1 |
“U.S. Tax Compliance Certificate” | Exhibit C, Section 7(b)(ii)(C) |
“Withholding Agent” | Exhibit C, Section 1 |
In addition to the terms defined elsewhere in this Agreement, the following terms have the following meanings:
2
US-DOCS ###-###-####.3
3
US-DOCS ###-###-####.3
4
US-DOCS ###-###-####.3
5
US-DOCS ###-###-####.3
“FDA” means the U.S. Food and Drug Administration or any successor thereto.
6
US-DOCS ###-###-####.3
7
US-DOCS ###-###-####.3
8
US-DOCS ###-###-####.3
“Net Product Revenue” means, with respect to Borrower and its Subsidiaries who are Guarantors (including Subsidiaries acquired by Borrower who become Guarantors in connection with a Permitted Investment), product revenue (determined under GAAP) of Borrower’s and such Subsidiaries’ sale (either directly or through a lease or distribution arrangement and solely to the extent reported as revenue on Borrower’s consolidated financial statements) to non-Affiliates in the ordinary course of business of its products and related services directly sold in connection with such products, including, for the avoidance of doubt revenue in connection with NeuroStar® Advanced Therapy Systems and upgrades thereto, NeuroStar Treatment Sessions (whether on a “per click” or capitated basis), TrakStar Cloud and service contracts, but excluding, in each case, revenue (a) in connection with any one time or extraordinary transactions, (b) attributable to licensing, collaboration or similar arrangements (including for the avoidance
9
US-DOCS ###-###-####.3
of doubt Permitted Licenses), (c) related to the sale of assets other than products in the ordinary course of business, (d) any revenue related to the leasing or distribution of products and services other than in each case the sale of inventory and related services through leasing or distribution arrangements that would otherwise constitute ordinary course of business sales of such products and services, (e) from any royalty, collaboration, commission or similar arrangement, and (f) without duplication, any other transaction (unless specifically specified in this proviso) that would not be an arms-length sales transaction entered into in the ordinary course of business. For the avoidance of doubts, Transfers of products and services to HCA under the HCA Agreement are deemed to be a sale to a Non-Affiliate in the ordinary course of business.
10
US-DOCS ###-###-####.3
11
US-DOCS ###-###-####.3
12
US-DOCS ###-###-####.3
13
US-DOCS ###-###-####.3
14
US-DOCS ###-###-####.3
15
US-DOCS ###-###-####.3
16
US-DOCS ###-###-####.3
17
US-DOCS ###-###-####.3
2. | LOANS AND TERMS OF PAYMENT |
18
US-DOCS ###-###-####.3
19
US-DOCS ###-###-####.3
3. | CONDITIONS OF LOANS |
20
US-DOCS ###-###-####.3
21
US-DOCS ###-###-####.3
22
US-DOCS ###-###-####.3
23
US-DOCS ###-###-####.3
4. | CREATION OF SECURITY INTEREST |
If this Agreement is terminated, Collateral Agent’s Lien in the Collateral shall continue until the Obligations (other than inchoate indemnity obligations) are repaid in full in cash. Upon payment in full in cash of the Obligations (other than inchoate indemnity obligations) and at such time as the Lenders’ obligation to extend Term Loans has terminated, Collateral Agent shall, at the sole cost and expense of Borrower, release its Liens in the Collateral and all rights therein shall revert to Borrower.
5. | REPRESENTATIONS AND WARRANTIES |
Borrower represents and warrants to Collateral Agent and the Lenders as follows:
24
US-DOCS ###-###-####.3
The execution, delivery and performance by Borrower and each of its Subsidiaries of the Loan Documents to which it is, or they are, a party have been duly authorized, and do not (i) conflict with any of Borrower’s or such Subsidiaries’ organizational documents, including its respective Operating Documents, (ii) contravene, conflict with, constitute a default under or violate any material Requirement of Law applicable thereto, (iii) contravene, conflict or violate any applicable order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which Borrower or such Subsidiary, or any of their property or assets may be bound or affected, (iv) require any action by, filing, registration, or qualification with, or Governmental Approval from, any Governmental Authority (except such Governmental Approvals which have already been obtained and are in full force and effect) or are being obtained pursuant to Section 6.1(b), or (v) constitute an event of default under any material agreement by which Borrower, any of its Subsidiaries or any of their respective properties, is bound. Neither Borrower nor any of its Subsidiaries is in default under any agreement to which it is a party or by which it or any of its assets is bound in which such default could reasonably be expected to have a Material Adverse Change.
25
US-DOCS ###-###-####.3
None of Borrower, any of its Subsidiaries, or any of Borrower’s or its Subsidiaries’ Affiliates or any of their respective agents acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement is (i) in violation of any Anti-Terrorism Law, (ii) engaging in or conspiring to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law, or (iii) is a Blocked Person. None of Borrower, any of its Subsidiaries, or to the Knowledge of Borrower and any of their Affiliates or agents, acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement, (x) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (y) deals in, or otherwise engages in any transaction relating to, any property or interest in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti-Terrorism Law.
26
US-DOCS ###-###-####.3
good faith contests its obligation to pay the Taxes by appropriate proceedings promptly and diligently instituted and conducted; (b) notifies Collateral Agent of the commencement of, and any material development in, the proceeding; and (c) maintains adequate reserves or other appropriate provisions on its books in accordance with GAAP, provided, further, that such action would not involve, in the reasonable judgment of Collateral Agent, any risk of the sale, forfeiture or loss of any material portion of the Collateral. Neither Borrower nor any of its Subsidiaries is aware of any claims or adjustments proposed for any of Borrower’s or such Subsidiary’s prior Tax years which could result in additional Taxes becoming due and payable by Borrower or its Subsidiaries. Borrower and each of its Subsidiaries have paid all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with their terms, and neither Borrower nor any of its Subsidiaries has withdrawn from participation in, has permitted partial or complete termination of, or has permitted the occurrence of any other event with respect to, any such plan which could reasonably be expected to result in any liability of Borrower or its Subsidiaries, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other Governmental Authority.
6. | AFFIRMATIVE COVENANTS |
Borrower shall, and shall cause each of its Subsidiaries to, do all of the following:
27
US-DOCS ###-###-####.3
28
US-DOCS ###-###-####.3
Notwithstanding the foregoing, the financial statements or other reports required to be delivered pursuant to clauses (ii), (iii) and (iv) above may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which Borrower posts such documents, or provides a link thereto, on Borrower’s website on the internet at Borrower’s website address.
29
US-DOCS ###-###-####.3
30
US-DOCS ###-###-####.3
all losses under all casualty policies in any one year, toward the replacement promptly or repair of destroyed or damaged property; provided that any such replaced or repaired property (i) shall be of equal or like value as the replaced or repaired Collateral and (ii) shall be deemed Collateral in which Collateral Agent has been granted a first priority security interest, and (b) after the occurrence and during the continuance of an Event of Default, all proceeds payable under such casualty policy shall, at the option of Collateral Agent, be payable to Collateral Agent, for the ratable benefit of the Lenders, on account of the Obligations. If Borrower or any of its Subsidiaries fails to obtain insurance as required under this Section 6.5 or to pay any amount or furnish any required proof of payment to third persons, Collateral Agent and/or any Lender may make (but has no obligation to do so), at Borrower’s expense, all or part of such payment or obtain such insurance policies required in this Section 6.5, and take any action under the policies Collateral Agent or such Lender deems prudent.
31
US-DOCS ###-###-####.3
7. | NEGATIVE COVENANTS |
Borrower shall not, and shall not permit any of its Subsidiaries to, do any of the following without the prior written consent of the Required Lenders:
32
US-DOCS ###-###-####.3
33
US-DOCS ###-###-####.3
increase the amount thereof or adversely affect the subordination thereof to Obligations owed to the Lenders.
Measurement Period Ending | Minimum Net Product Revenue |
March 31, 2024 | [***] |
April 30, 2024 | [***] |
34
US-DOCS ###-###-####.3
May 31, 2024 | [***] |
June 30, 2024 | [***] |
July 31, 2024 | [***] |
August 31, 2024 | [***] |
September 30, 2024 | [***] |
October 31, 2024 | [***] |
November 30, 2024 | [***] |
December 31, 2024 | [***] |
January 31, 2025 | [***] |
February 28, 2025 | [***] |
8. | EVENTS OF DEFAULT |
Any one of the following shall constitute an event of default (an “Event of Default”) under this Agreement:
35
US-DOCS ###-###-####.3
36
US-DOCS ###-###-####.3
9. | RIGHTS AND REMEDIES |
37
US-DOCS ###-###-####.3
38
US-DOCS ###-###-####.3
Notwithstanding any provision of this Section 9.1 to the contrary, upon the occurrence of any Event of Default, Collateral Agent shall have the right to exercise any and all remedies referenced in this Section 9.1 without the written consent of Required Lenders following the occurrence of an Exigent Circumstance.
39
US-DOCS ###-###-####.3
under the Loan Documents. Any balance remaining shall be delivered to Borrower or to whoever may be lawfully entitled to receive such balance or as a court of competent jurisdiction may direct. In carrying out the foregoing, (x) amounts received shall be applied in the numerical order provided until exhausted prior to the application to the next succeeding category, and (y) each of the Persons entitled to receive a payment in any particular category shall receive an amount equal to its pro rata share of amounts available to be applied pursuant thereto for such category. Any reference in this Agreement to an allocation between or sharing by the Lenders of any right, interest or obligation “ratably,” “proportionally” or in similar terms shall refer to the Lenders’ Pro Rata Shares unless expressly provided otherwise. Collateral Agent, or if applicable, each Lender, shall promptly remit to the other Lenders such sums as may be necessary to ensure the ratable repayment of each Lender’s Pro Rata Share of any Term Loan and the ratable distribution of interest, fees and reimbursements paid or made by Borrower. Notwithstanding the foregoing, a Lender receiving a scheduled payment shall not be responsible for determining whether the other Lenders also received their scheduled payment on such date; provided, however, if it is later determined that a Lender received more than its Pro Rata Share of scheduled payments made on any date or dates, then such Lender shall remit to Collateral Agent or other the Lenders such sums as may be necessary to ensure the ratable payment of such scheduled payments, as instructed by Collateral Agent. If any payment or distribution of any kind or character, whether in cash, properties or securities, shall be received by a Lender in excess of its Pro Rata Share, then the portion of such payment or distribution in excess of such Lender’s Pro Rata Share shall be received and held by such Lender in trust for and shall be promptly paid over to the other Lenders (in accordance with their respective Pro Rata Shares) for application to the payments of amounts due on such other Lenders’ claims. To the extent any payment for the account of Borrower is required to be returned as a voidable transfer or otherwise, the Lenders shall contribute to one another as is necessary to ensure that such return of payment is on a pro rata basis. If any Lender shall obtain possession of any Collateral, it shall hold such Collateral for itself and as agent and bailee for the Secured Parties for purposes of perfecting Collateral Agent’s security interest therein (held for the ratable benefit of the Secured Parties).
40
US-DOCS ###-###-####.3
10. | NOTICES |
Other than as specifically provided herein, all notices, consents, requests, approvals, demands, or other communication (collectively, “Communications”) by any party to this Agreement or any other Loan Document must be in writing and shall be deemed to have been validly served, given, or delivered: (a) upon the earlier of actual receipt and three (3) Business Days after deposit in the U.S. mail, first class, registered or certified mail return receipt requested, with proper postage prepaid; (b) upon transmission, when sent by electronic mail or facsimile transmission; (c) one (1) Business Day after deposit with a reputable overnight courier with all charges prepaid; or (d) when delivered, if hand-delivered by messenger, all of which shall be addressed to the party to be notified and sent to the address, facsimile number, or email address indicated below. Any of Collateral Agent, Lender or Borrower may change its mailing address or facsimile number by giving the other party written notice thereof in accordance with the terms of this Section 10.
If to Borrower: | NEURONETICS, INC. 3222 Phoenixville Pike Malvern, PA 19355 Attn: Chief Financial Officer Email: [***] |
| |
with a copy to: | NEURONETICS, INC. 3222 Phoenixville Pike Malvern, PA 19355 Attn: General Counsel Fax: Email: [***] |
| |
with a copy (which shall not constitute notice) to: | Morrison & Foerster LLP 250 West 55th Street New York, NY 10019 Attn: Geoff Peck Email: [***] |
| |
If to Collateral Agent: | SOLAR CAPITAL LTD. 500 Park Avenue, 3rd Floor New York, NY 10022 Attention: Anthony Storino Fax: [***] Email: [***] |
| |
| |
with a copy (which shall not constitute notice) to: | LATHAM & WATKINS LLP 505 Montgomery Street, Suite 2000 San Francisco, CA 94111 Attention: Haim Zaltzman Facsimile: [***] Email: [***] |
| |
41
US-DOCS ###-###-####.3
11. | CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER |
42
US-DOCS ###-###-####.3
provided therein). Borrower agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.
12. | GENERAL PROVISIONS |
43
US-DOCS ###-###-####.3
44
US-DOCS ###-###-####.3
45
US-DOCS ###-###-####.3
The obligation of Borrower in Section 12.2 to indemnify each Lender and Collateral Agent, as well as the confidentiality provisions in Section 12.8 below, shall survive until the statute of limitations with respect to such claim or cause of action shall have run.
46
US-DOCS ###-###-####.3
conducted no more often than twice every twelve months unless an Event of Default has occurred and is continuing), and (iii) assist Collateral Agent and the Lenders in the preparation of information relating to the financial affairs of Borrower as any prospective participant or assignee of a Term Loan Commitment (or portions thereof) or Term Loan (or portions thereof) reasonably may request. Subject to the provisions of Section 12.8, Borrower authorizes each Lender to disclose to any prospective participant or assignee of a Term Loan Commitment (or portions thereof), any and all information in such Lender’s possession concerning Borrower and its financial affairs which has been delivered to such Lender by or on behalf of Borrower pursuant to this Agreement, or which has been delivered to such Lender by or on behalf of Borrower in connection with such Lender’s credit evaluation of Borrower prior to entering into this Agreement.
[Balance of Page Intentionally Left Blank]
47
US-DOCS ###-###-####.3
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the Effective Date.
BORROWER: | | |
| | |
NEURONETICS, INC. | | |
| | |
| | |
By | | |
Name: | | |
Title: | | |
| | |
| | |
[Signature Page to Loan and Security Agreement]
US-DOCS ###-###-####.4#56974094 v2
COLLATERAL AGENT AND LENDER: | | |
| | |
SOLAR CAPITAL LTD. | ||
| | |
| | |
By | | |
Name: | | |
Title: | | |
| | |
| | |
[Signature Page to Loan and Security Agreement]
US-DOCS ###-###-####.4#56974094 v2
LENDERS: | | |
| | |
SUNS SPV LLC | ||
| | |
| | |
By | | |
Name: Anthony Storino | | |
Title: Authorized Signatory | | |
| | |
| | |
SCP PRIVATE CREDIT INCOME FUND SPV LLC | ||
| | |
| | |
By | | |
Name: Anthony Storino | | |
Title: Authorized Signatory | | |
| | |
| | |
SCP PRIVATE CREDIT INCOME BDC SPV LLC | ||
| | |
| | |
By | | |
Name: Anthony Storino | | |
Title: Authorized Signatory | | |
| | |
| | |
SCP PRIVATE CORPORATE LENDING FUND SPV LLC | ||
| | |
| | |
By | | |
Name: Anthony Storino | | |
Title: Authorized Signatory | | |
| | |
| | |
SCP SF DEBT FUND L.P. | ||
| | |
| | |
By | | |
Name: Anthony Storino | | |
Title: Authorized Signatory | | |
[Signature Page to Loan and Security Agreement]
US-DOCS ###-###-####.4#56974094 v2
Lenders and Commitments
| Term A Loans | |
Lender | Term Loan Commitment | Commitment Percentage |
SLR Investment Corp. | $5,612,935.51 | 16.037% |
SUNS SPV LLC | $12,399,509.81 | 35.427% |
SCP Private Credit Income Fund SPV LLC | $4,096,038.24 | 11.703% |
SCP Private Credit Income BDC SPV LLC | $3,055,625.78 | 8.730% |
SCP Private Corporate Lending Fund SPV LLC | $5,549,578.80 | 15.856% |
SCP Cayman Debt Master Fund SPV LLC | $2,374,202.48 | 6.783% |
SLR CP SF Debt Fund SPV LLC | $1,912,109.38 | 5.463% |
TOTAL | $35,000,000.00 | 100.00% |
| Term B Loans | |
Lender | Term Loan Commitment | Commitment Percentage |
SLR Investment Corp. | $1,286,603.24 | 51.464% |
SCP Private Credit Income Fund L.P. | $292,574.16 | 11.703% |
SCP Private Credit Income BDC LLC | $218,258.98 | 8.730% |
SCP Private Corporate Lending Fund SPV LLC | $396,398.49 | 15.856% |
SCP Cayman Debt Master Fund SPV LLC | $169,585.89 | 6.783% |
SLR CP SF Debt Fund SPV LLC | $136,579.24 | 5.463% |
TOTAL | $2,500,000.00 | 100.00% |
| Term C Loans | |
Lender | Term Loan Commitment | Commitment Percentage |
SLR Investment Corp. | $11,579,429.16 | 51.464% |
SCP Private Credit Income Fund L.P. | $2,633,167.44 | 11.703% |
SCP Private Credit Income BDC LLC | $1,964,330.82 | 8.730% |
SCP Private Corporate Lending Fund SPV LLC | $3,567,586.41 | 15.856% |
SCP Private Corporate Lending Fund L.P. | $1,526,273.01 | 6.783% |
SLR CP SF Debt Fund SPV LLC | $1,229,213.16 | 5.463% |
TOTAL | $22,500,000.00 | 100.00% |
US-DOCS ###-###-####.3
Aggregate
Lender | Term Loan Commitment | Commitment Percentage |
SLR Investment Corp. | $18,478,967.91 | 30.798% |
SUNS SPV LLC | $12,399,509.81 | 20.666% |
SCP Private Credit Income Fund SPV LLC | $4,096,038.24 | 6.827% |
SCP Private Credit Income Fund L.P. | $2,925,741.60 | 4.876% |
SCP Private Credit Income BDC SPV LLC | $3,055,625.78 | 5.093% |
SCP Private Credit Income BDC LLC | $2,182,589.80 | 3.638% |
SCP Private Corporate Lending Fund SPV LLC | $9,513,563.70 | 15.856% |
SCP Private Corporate Lending Fund L.P. | $1,526,273.01 | 2.544% |
SCP Cayman Debt Master Fund SPV LLC | $2,543,788.37 | 4.240% |
SLR CP SF Debt Fund SPV LLC | $3,277,901.78 | 5.463% |
TOTAL | $60,000,000.00 | 100.00% |
US-DOCS ###-###-####.3
The Collateral consists of all of Borrower’s right, title and interest in and to the following property:
All goods, Accounts (including health-care receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements, franchise agreements, General Intangibles, commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts and other Collateral Accounts, all certificates of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located; and
All Borrower’s Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing.
Notwithstanding the foregoing, the Collateral does not include (a) any interest of Borrower as a lessee or sublessee under a real property lease; (b) rights held under a license that are not assignable by their terms without the consent of the licensor thereof (but only to the extent such restriction on assignment is effective under Section 9-406, 9-407, 9-408 or 9-409 of the Code (or any successor provision or provisions) of any relevant jurisdiction or any other applicable law (including the Bankruptcy Code) or principles of equity); (c) any interest of Borrower as a lessee under an Equipment lease if Borrower is prohibited by the terms of such lease from granting a security interest in such lease or under which such an assignment or Lien would cause a default to occur under such lease; and (d) any “intent to use” United States Trademark applications for which a statement of use or an amendment to allege use has not been filed (but only until such statement is filed) solely to the extent, if any, that, and only during the period, if any, in which, the grant of a security interest therein would impair the validity or enforceability of such intent to use Trademark applications under applicable federal law provided, however, that upon termination of such prohibition, such interest shall immediately become Collateral without any action by Borrower, Collateral Agent or any Lender.
US-DOCS ###-###-####.3
US-DOCS ###-###-####.3
US-DOCS ###-###-####.3
US-DOCS ###-###-####.3
US-DOCS ###-###-####.3
Borrower as required under the Loan Documents (including pursuant to Section 12.2 of the Agreement)), ratably according to its Pro Rata Share, from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind or nature whatsoever (including, to the extent not indemnified by the applicable Lender, Taxes, interests and penalties imposed for not properly withholding or backup withholding on payments made to or for the account of any Lender) that may be imposed on, incurred by, or asserted against Collateral Agent or any of its Related Persons in any matter relating to or arising out of, in connection with or as a result of any Loan Document or any other act, event or transaction related, contemplated in or attendant to any such document, or, in each case, any action taken or omitted to be taken by Collateral Agent or any of its Related Persons under or with respect to the foregoing; provided that no Lender shall be liable to Collateral Agent or any of its Related Persons under this Section 6 of this Exhibit B to the extent such liability has resulted from the gross negligence or willful misconduct of Collateral Agent or, as the case may be, such Related Person, as determined by a final non-appealable judgment of a court of competent jurisdiction. To the extent required by any applicable Requirement of Law, Collateral Agent may withhold from any payment to any Lender under a Loan Document an amount equal to any applicable withholding Tax. If the IRS or any other Governmental Authority asserts a claim that Collateral Agent did not properly withhold Tax from amounts paid to or for the account of any Lender for any reason, or if Collateral Agent reasonably determines that it was required to withhold Taxes from a prior payment to or for the account of any Lender but failed to do so, such Lender shall promptly indemnify Collateral Agent fully for all amounts paid, directly or indirectly, by Collateral Agent as Tax or otherwise, including penalties and interest, and together with all expenses incurred by Collateral Agent. Collateral Agent may offset against any payment to any Lender under a Loan Document, any applicable withholding Tax that was required to be withheld from any prior payment to such Lender but which was not so withheld, as well as any other amounts for which Collateral Agent is entitled to indemnification from such Lender under the immediately preceding sentence of this Section 6 of this Exhibit B.
US-DOCS ###-###-####.3
US-DOCS ###-###-####.3
US-DOCS ###-###-####.3
US-DOCS ###-###-####.3
US-DOCS ###-###-####.3
(A) | in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “interest” article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “business profits” or “other income” article of such tax treaty; |
(B) | executed copies of IRS Form W-8ECI; |
(C) | in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Internal Revenue Code, (x) a certificate, in form and substance reasonably acceptable to Borrower and Collateral Agent, to the effect that such Foreign Lender (or other applicable Person) is not a “bank” within the meaning of Section 881(c)(3)(A) of the Internal Revenue Code, a “10 percent shareholder” of Borrower within the meaning of Section 871(h)(3)(B) of the Internal Revenue Code, or a “controlled foreign corporation” related to Borrower as described in |
US-DOCS ###-###-####.3
Section 881(c)(3)(C) of the Internal Revenue Code (a “U.S. Tax Compliance Certificate”) and (y) executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E; or |
(D) | to the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN, IRS Form W-8BEN-E, a U.S. Tax Compliance Certificate, IRS Form W-9, and/or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate on behalf of each such direct and indirect partner; |
US-DOCS ###-###-####.3
event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this Section 8 the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This Section 8 shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.
US-DOCS ###-###-####.3
Fax To: (212) 993-1698Date: _____________________
Loan Payment:
Neuronetics, Inc.
From Account #________________________________To Account #__________________________________________________
(Deposit Account #)(Loan Account #)
Principal $____________________________________and/or Interest $________________________________________________
Authorized Signature: Phone Number:
Print Name/Title:
Loan Advance:
Complete Outgoing Wire Request section below if all or a portion of the funds from this loan advance are for an outgoing wire.
From Account #________________________________To Account #__________________________________________________
(Loan Account #)(Deposit Account #)
Amount of Advance $___________________________
All Borrower’s representations and warranties in the Loan and Security Agreement are true, correct and complete in all material respects on the date of the request for an advance; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date:
Authorized Signature: Phone Number:
Print Name/Title:
Outgoing Wire Request:
Complete only if all or a portion of funds from the loan advance above is to be wired.
Beneficiary Name: _____________________________ Amount of Wire: $
Beneficiary Bank: ______________________________ Account Number:
City and State:
US-DOCS ###-###-####.3
Beneficiary Bank Transit (ABA) #: Beneficiary Bank Code (Swift, Sort, Chip, etc.):
(For International Wire Only)
Intermediary Bank: Transit (ABA) #:
For Further Credit to:
Special Instruction:
By signing below, I (we) acknowledge and agree that my (our) funds transfer request shall be processed in accordance with and subject to the terms and conditions set forth in the agreements(s) covering funds transfer service(s), which agreements(s) were previously received and executed by me (us).
Authorized Signature: ___________________________2nd Signature (if required): _______________________________________
Print Name/Title: ______________________________Print Name/Title: ______________________________________________
Telephone #: Telephone #: ]
US-DOCS ###-###-####.3
TO: | SOLAR CAPITAL LTD., as Collateral Agent and Lender |
FROM: | Neuronetics, Inc. |
The undersigned authorized officer (“Officer”) of Neuronetics, Inc. (“Borrower”), hereby certifies that in accordance with the terms and conditions of the Loan and Security Agreement dated as of March 2, 2020, by and among Borrower, Collateral Agent, and the Lenders from time to time party thereto (the “Loan Agreement;” capitalized terms used but not otherwise defined herein shall have the meanings given them in the Loan Agreement),
Attached are the required documents, if any, supporting Borrower’s certification(s). The Officer, on behalf of Borrower, further certifies that the attached financial statements are prepared in accordance with Generally Accepted Accounting Principles (GAAP) and are consistently applied from one period to the next except as explained in an accompanying letter or footnotes and except, in the case of unaudited financial statements, for the absence of footnotes and subject to year-end audit adjustments as to the interim financial statements.
Please indicate compliance status since the last Compliance Certificate by circling Yes, No, or N/A under “Complies” column.
| Reporting Covenant | Requirement | Actual | Complies | ||
1) | Monthly financial statements | Monthly within 30 days | | Yes | No | N/A |
2) | Quarterly financial statements | Quarterly within 45 days | | Yes | No | N/A |
US-DOCS ###-###-####.3
3) | Annual (CPA Audited) statements | Within 90 days after FYE | | Yes | No | N/A |
4) | Annual Financial Projections/Budget (prepared on a monthly basis) | Annually (within earlier of 10 days of approval or 60 days after FYE), and when revised | | Yes | No | N/A |
5) | A/R & A/P agings | If applicable | | Yes | No | N/A |
6) | 8-K, 10-K and 10-Q Filings | within 5 days of filing | | Yes | No | N/A |
7) | Compliance Certificate | Monthly within 30 days | | Yes | No | N/A |
8) | IP Report | When required | | Yes | No | N/A |
9) | Total amount of Borrower’s cash and cash equivalents at the last day of the measurement period | | $________ | Yes | No | N/A |
10) | Total amount of Borrower’s Subsidiaries’ cash and cash equivalents at the last day of the measurement period | | $________ | Yes | No | N/A |
Deposit and Securities Accounts
(Please list all accounts; attach separate sheet if additional space needed)
| Institution Name | Account Number | New Account? | Account Control Agreement in place? | ||
1) | | | Yes | No | Yes | No |
2) | | | Yes | No | Yes | No |
3) | | | Yes | No | Yes | No |
4) | | | Yes | No | Yes | No |
Financial Covenants
Minimum Liquidity Requirement | (A) Qualified Cash $___________ | (B) A/P not paid within 90 days from invoice date $____________ | Complies with Minimum Liquidity Requirement (Is (A) greater than or equal to $10,000,000 plus (B)? | ||
| | | | | YNN/A |
Minimum Product Revenue (period ending __________) | (A) Actual Product Revenue $___________ | (B) Minimum Product Revenue per Section 7.13(b) $____________ | Complies with Minimum Product Revenue (Is (A) greater than or equal to (B))? | ||||||
| | | Y | N | N/A |
US-DOCS ###-###-####.3
Other Matters
1) | Have there been any changes in Key Persons since the last Compliance Certificate? | Yes | No |
| | | |
2) | Have there been any transfers/sales/disposals/retirement of Collateral or IP prohibited by the Loan Agreement? | Yes | No |
| | | |
3) | Have there been any new or pending claims or causes of action against Borrower that involve more than One Hundred Thousand Dollars ($100,000.00)? | Yes | No |
| | | |
4) | Have there been any amendments of or other changes to the capitalization table of Borrower and to the Operating Documents of Borrower or any of its Subsidiaries? If yes, provide copies of any such amendments or changes with this Compliance Certificate. | Yes | No |
5) | Has Borrower or any Subsidiary entered into or amended any Material Agreement? If yes, please explain and provide a copy of the Material Agreement(s) and/or amendment(s). | Yes | No |
| | | |
6) | Has Borrower provided the Collateral Agent with all notices required to be delivered under Sections 6.2(a) and 6.2(c) of the Loan Agreement? | Yes | No |
US-DOCS ###-###-####.3
Exceptions
Please explain any exceptions with respect to the certification above: (If no exceptions exist, state “No exceptions.” Attach separate sheet if additional space needed.)
NEURONETICS, INC.
By:
Name:
Title:
Date:
COLLATERAL AGENT USE ONLY | |
| |
Received by: | Date: |
| |
Verified by: | Date: |
| |
Compliance Status:YesNo |
US-DOCS ###-###-####.3
SLR INVESTMENT CORP.
500 Park Avenue, 3rd Floor
New York, NY 10022
Attention: Anthony Storino
Fax: (212) 993-1698
Email: ***@***
Re: Loan and Security Agreement dated as of March 2, 2020 (the “Agreement”) by and among Neuronetics, Inc. (“Borrower”), SLR Investment Corp. (formerly, Solar Capital Ltd.) (“Solar”), as collateral agent (in such capacity, “Collateral Agent”) and the Lenders listed on Schedule 1.1 thereof or otherwise a party thereto from time to time, including Solar in its capacity as a Lender and Collateral Agent (each a “Lender” and collectively, the “Lenders”). Capitalized terms used but not otherwise defined herein shall have the meanings given them under the Agreement.
In connection with the above referenced Agreement, the Borrower hereby authorizes the Collateral Agent to, at its discretion and with prior notice of at least one (1) Business Day, initiate debit entries to the Borrower’s account indicated below (i) on each payment date of all Obligations then due and owing, (ii) at any time any payment due and owing with respect to Lender Expenses, and (iii) upon an Event of Default, any other Obligations outstanding, in each case pursuant to Section 2.3(e) of the Agreement. The Borrower authorizes the depository institution named below to debit to such account.
Depository Name | Branch |
City | State and Zip Code |
Transit/ABA Number | Account Number |
This authority will remain in full force and effect so long as any amounts are due under the Agreement.
NEURONETICS, INC.
By: _________________________________________
Title: ________________________________________
Date: ________________________________________
US-DOCS ###-###-####.3